South America Ovarian Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

The rising incidences of ovarian cancer are one of the primary drivers for the market. The cancer burden is increasing, owing to factors such as the aging population, poor diet, smoking, and physical inactivity. According to Globocan, in 2018, there were around 243,588 deaths due to cancer in Brazil. Ovarian cancer (OC) is the most common cancer among women. OC has a high mortality rate and is difficult to diagnose. Due to its silent progression, it is contributing to the high mortality rate. Thus, due to the increasing incidence of ovarian cancer, the market for cancer diagnostics and therapeutics is expected to see stable growth in South America. Additionally, the rising geriatric population and increase in healthcare expenditure also contribute to the growth of the market.

Key Market Trends

CT Scan Segment is Expected to Show Better Growth in the Forecast Years

• Based on Diagnosis, the market is segmented into Biopsy, Blood Tests, Ultrasound, PET, CT Scan and Other Diagnosis.
• Computed Tomography (CT) is an imaging procedure that uses special X-ray equipment to create detailed pictures, or scans, of areas inside the body. It is also called computerized tomography and computerized axial tomography (CAT). These equipment do not show small ovarian tumors well, but they can see larger tumors and may be able to see if the tumor is growing into nearby structures.
• The use of modern CT machines with robot-assisted surgical systems is improving surgical outcomes. Hence, CT machines are the highly beneficial and preferred method of imaging for many conditions, which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The market for ovarian cancer diagnostics and therapeutics market in South America is moderately competitive and consists of the global players such as AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson and Siemens AG, Furthermore, with rising technological advancements and innovation, more companies are expected to penetrate the market in the coming future.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format.
• 3 months of analyst support.

This product will be delivered within 2 business days.